Skip to content
A4572Assembly2021-2022 SessionSame asS4316

Expand Newborn Disease Screening

Official title

“Relates to the screening of newborns for certain diseases and conditions”

Sponsor Richard GottfriedAD-75+1 co-sponsorAffects Health
Status
Signed by Governor
Impact
6/10
Moderate
Outcome
Signed into law

Bill progress

Signed into law

What's happening

This bill updates newborn screening requirements to specifically include adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficiency.

Why it matters

  1. Specifying these two additional conditions (adrenoleukodystrophy and G6PD deficiency) in statute guarantees that all newborns in New York will be screened for them, regardless of future changes in regulations or administrative priorities.

  2. Early detection of adrenoleukodystrophy and G6PD deficiency through mandatory screening can significantly improve health outcomes, as both conditions can be managed or treated more effectively if caught before symptoms develop.

  3. Families may have earlier access to information and support services for these specific genetic conditions, reducing diagnostic delays and potentially avoiding severe complications or even fatalities.

  4. By updating the law to enumerate these diseases, the bill also increases transparency for parents and health providers about what is included in newborn screening, making it clearer what to expect and advocate for.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Expand Newborn Disease Screening

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Richard Gottfried

Assembly Member · Assembly District 75

1 Co-sponsor

1 Multi-sponsor

History

  1. Approval memo.97
  2. Signed chap.730
  3. Delivered to governor
  4. Returned to assembly
  5. Passed senateVote 63–0
  6. 3rd reading cal.722
  7. Substituted for S4316
  8. Referred to finance
  9. Delivered to senate
  10. Passed assembly
  11. Advanced to third reading cal.130
  12. Reported
Show 1 earlier action
  1. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S4316Senate

Expand Newborn Disease Screening

Senate Floor Calendar · Sponsor Gustavo Rivera

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

4572

2021-2022 Regular Sessions

IN ASSEMBLY

February 4, 2021

Introduced by M. of A. GOTTFRIED -- read once and referred to the Committee on Health

AN ACT to amend the public health law, in relation to newborn screening for adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficiency

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Section 2500-a of the public health law, as separately amended by chapters 943 and 1016 of the laws of 1974, subdivision (a) as amended by chapter 307 of the laws of 2018 and subdivision (c) as added by section 113 of part E of chapter 56 of the laws of 2013, is amended to read as follows:

§ 2500-a. Test for phenylketonuria and other diseases and conditions. [(a)] 1. It shall be the duty of the administrative officer or other person in charge of each institution caring for infants twenty-eight days or less of age and the person required in pursuance of the provisions of section forty-one hundred thirty of this chapter to register the birth of a child, to cause to have administered to every such infant or child in its or his care a test for diseases and conditions designated by the commissioner under regulations of the commissioner, and for:

[i. phenylketonuria,

ii. homozygous sickle cell disease,

iii. hypothyroidism,

iv. branched-chain ketonuria,

v. galactosemia,

vi. homocystinuria,

vii. critical congenital heart defects through pulse oximetry screening,

viii. with] (a) Phenylketonuria.

(b) Homozygous sickle cell disease.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD00136-01-1

A. 4572 2

(c) Hypothyroidism.

(d) Branched-chain ketonuria.

(e) Galactosemia.

(f) Homocystinuria.

(g) Critical congenital heart defects through pulse oximetry screening.

(h) With regard to any newborn infant who is identified as, or suspected of, having a hearing impairment as a result of a screening conducted pursuant to section twenty-five hundred-g of this title, [cause to be administered to such infant] a urine polymerase chain reaction (PCR) test for cytomegalovirus, unless the parent of the infant objects thereto; provided that if the commissioner determines that another test for cytomegalovirus is diagnostically equivalent to or better than the urine polymerase chain reaction test, the commissioner may, by regulation under this section, allow or require the use of that other test[, and

ix. such other diseases and conditions as may from time to time be designated by the commissioner in accordance with rules or regulations prescribed by the commissioner].

(i) Adrenoleukodystrophy.

(j) Glucose-6-phosphate dehydrogenase deficiency.

2. Testing, the recording of the results of such tests, tracking, follow-up reviews and educational activities shall be performed at such times and in such manner as may be prescribed by the commissioner. The commissioner shall promulgate regulations setting forth the manner in which information describing the purposes of the requirements of this section shall be disseminated to parents or a guardian of the infant tested.

[(b)] 3. The provisions of this section shall not apply in the case of any infant or child whose parent or guardian is a member of a recognized religious organization whose teachings and tenets are contrary to the testing herein required and who notifies the person charged with having such test administered of his objection thereto.

[(c) By regulation, the commissioner shall add adrenoleukodystrophy ("ALD") to the list of diseases and conditions for which testing shall be performed pursuant to subdivision (a) of this section upon validation by the Wadsworth Center of a test for ALD. The Wadsworth Center shall undertake the process for validation upon the development of a test. This subdivision shall be known and may be cited as "Aidan's Law."]

§ 2. This act shall take effect on the one hundred eightieth day after it shall have become a law. Effective immediately, the commissioner of health shall make regulations and take other actions reasonably necessary to implement this act on that date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.